Chembio signs $480k agreement with CDC contractor for influenza test
Chembio's multiplex rapid point-of-care influenza immunity test uses the company's patented Dual Path Platform technology. The test may allow for faster responses in the field, including the isolation, vaccination or prophylactic treatment of influenza. The development of rapid tests is important for military forces to prevent influenza outbreaks from spreading through densely populated barracks.
Chembio entered into a six-month agreement with a private contracting organization that is engaged to enter into, implement and provide technical oversight of agreements connected to pandemic preparedness on behalf of the CDC. The prior development contract for the product was completed by Chembio in 2010-11 pursuant to a $900,000 contract with the same contractor.
"We are pleased to enter into this follow-on development program that builds on our strength in developing multiplex products using our proprietary DPP® technology," Javan Esfandiari, Chembio's senior vice president of research and development, said. "This product could become an important diagnostic tool during influenza outbreaks."
The objective of the follow-on project is to further develop a rapid influenza immunity test that can determine a person's influenza immunity status in the field or in an outpatient setting.
Chembio markets, licenses, manufactures and develops proprietary rapid diagnostic tests.